Bidiphar secures Vietnam National Brand status for cancer drugs

Bidiphar Pharmaceutical Joint Stock Company has had five products recognized as Vietnam National Brands for 2026. These include three cancer treatments—Bocartin (lung cancer), Lyoxatin (ovarian, head and neck cancer), and Bestdocel (breast and lung cancer)—as well as a hemodialysis solution and an anti-inflammatory/allergy medication.

The company is currently attracting significant interest from domestic and international institutional investors, including financial investors and pharmaceutical corporations. Key areas of interest include new factory investments, product strategies, pharmaceutical technology transfers, and international cooperation.

Bidiphar maintains a leading position in the domestic cancer drug market and operates two WHO-GMP standard factories with a total capacity of nearly 230 million products per year. Looking toward 2026, the company is focusing on strategic projects to upgrade its manufacturing capabilities, including a small-volume sterile drug factory and upgrading its Nhon Hoi cancer drug production line toward EU-GMP standards.